Baird analyst Jack Allen lowered the firm’s price target on MiNK Therapeutics (INKT) to $4 from $8 and keeps an Outperform rating on the shares. The firm said the company announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
Questions or Comments about the article? Write to editor@tipranks.com